Nasal Polyps: Navigating the Challenges and Opportunities in Clinical Trials

The diagnostic odyssey

Nasal polyps represent a significant burden for patients, often leading to chronic rhinosinusitis with nasal polyposis (CRSwNP). These benign growths in the nasal mucosa can result in a range of symptoms including nasal obstruction, loss of smell, and sinus infections. The journey to diagnosis can be prolonged and fraught with challenges, as many patients experience a lag in recognition of their condition. This is compounded by the variability in symptoms, which can lead to misdiagnosis or delayed treatment.

Eligible patients for clinical trials are particularly difficult to identify due to the heterogeneous nature of the disease. Factors such as co-existing conditions, variations in symptom severity, and differing responses to previous treatments complicate the selection process. Moreover, the stigma associated with chronic nasal issues often leads to underreporting, further obscuring the true prevalence of nasal polyps in the population. As a result, sponsors face challenges in recruiting suitable participants for trials aimed at exploring new treatment modalities.

The trial landscape right now

In our live trial registry, there are currently 11 recruiting trials across 23 sites in 6 countries, highlighting a concerted effort to address the needs of patients with nasal polyps. The trials encompass various phases, with 6 classified as N/A, 3 in Phase IV, 1 in Phase II, and 1 in Phase III. Notably, leading sponsors include Cliniques universitaires Saint-Luc - Université Catholique de Louvain, London Health Sciences Centre Research Institute, Ohio State University, Rigshospitalet in Denmark, and AstraZeneca.

Geographically, Belgium leads with 10 trials, followed by Denmark with 6, China with 3, the United States with 2, and France and Canada each hosting 1 trial. For example, NCT04869436, sponsored by the London Health Sciences Centre Research Institute, is a Phase IV trial investigating olfactory outcomes of dupilumab treatment for nasal polyposis. Another relevant trial, NCT05094570, led by the University of Virginia, focuses on interleukin-4Ra blockade and its effects on microbial diversity in CRSwNP. These trials reflect a growing interest in understanding and treating this complex condition.

How we detect the match

Leveraging an HL7/FHIR + AI layer can significantly enhance the identification of eligible patients for clinical trials without the burdensome process of manual chart review. By utilizing specific FHIR resources such as Condition, Observation, MedicationRequest, and DiagnosticReport, healthcare systems can efficiently surface potential candidates.

For instance, the Condition resource can help identify patients diagnosed with nasal polyps or CRSwNP based on ICD-10 codes. Observations related to symptoms such as nasal obstruction or loss of smell can be analyzed alongside MedicationRequest data to assess treatment history. The integration of lab results and genetic markers can further refine the search for eligible patients.

Computable phenotypes can be developed to encapsulate the multifaceted nature of nasal polyps, allowing for a more precise matching process that aligns with trial criteria. This approach not only streamlines the recruitment process but also ensures that patients who could benefit from innovative treatments are not overlooked.

Beyond the trial: better care

The integration of HL7/FHIR + AI not only enhances trial recruitment but also has the potential to improve patient care beyond the clinical trial setting. By facilitating better data sharing and interoperability among healthcare providers, patients can receive more coordinated and timely care.

For example, if a patient is identified as having nasal polyps but does not enroll in a trial, their care team can still utilize the insights gained through the integration process to tailor treatment strategies and monitor outcomes more effectively. This can lead to quicker diagnoses and improved management of chronic conditions, ultimately enhancing the patient's quality of life.

Moreover, by employing real-time data intelligence, healthcare systems can better track disease progression and treatment efficacy, ensuring that patients receive the most appropriate interventions based on their unique health profiles.

The takeaway

The landscape for nasal polyps is evolving, with a robust trial environment and innovative solutions to identify eligible patients. By embracing advanced integration technologies, stakeholders can improve not only trial recruitment but also the overall quality of care for those suffering from this challenging condition. As we move forward, the focus should remain on leveraging these advancements to enhance patient outcomes and streamline the diagnostic journey.